Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

In a sector of constant innovation, a company must be something special if even the experts are excited. These are the four ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

Bray, F., et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly has come back to the table with a new, wide-ranging deal worth up to $1.7 billion.

Talent Acquisition and Retention Pose Major Challenges for Life Sciences GCCs - Talent retention and acquisition are top ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

A Cambridge-based biotechnology firm developing antibody-based KnotBody drugs for ion channel- and G protein-coupled receptor (GPCR)-driven diseases, has raised £58m in a Series A financing.

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for people with genetically elevated cholesterol.